Strategies to reduce hepatitis C virus recurrence after liver transplantation (Q22305418)

8 February 2023

María Pleguezuelo

María

Pleguezuelo

1 reference

8 February 2023

Shirin Elizabeth Khorsandi

Shirin Elizabeth

Khorsandi

1 reference

8 February 2023

Diego Davila

Diego

Davila

1 reference

8 February 2023

Abid Suddle

Abid

Suddle

1 reference

8 February 2023

Hector Vilca-Melendez

Hector

Vilca-Melendez

1 reference

8 February 2023

Sebastian Rufian

Sebastian

Rufian

1 reference

8 February 2023

Manuel de la Mata

Manuel

de la Mata

1 reference

8 February 2023

Javier Briceño

Javier

Briceño

1 reference

8 February 2023

Pedro López Cillero

Pedro López

Cillero

1 reference

8 February 2023

Nigel Heaton

Nigel

Heaton

1 reference

World Journal of Hepatology

8 February 2023

language of work or name

English

0 references

publication date

27 May 2013

0 references

published in

1 reference

0 references

0 references

237-50

0 references

cites work

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Antiviral therapy for recurrent liver graft infection with hepatitis C virus

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Adoptive immunotherapy with liver allograft–derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Hepatitis C virus infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

The IL-28 Genotype: How It Will Affect the Care of Patients with Hepatitis C Virus Infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

New antiviral therapies for chronic hepatitis C

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Telaprevir for previously treated chronic HCV infection

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

The natural history of recurrent hepatitis C and what influences this

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Hepatitis C therapy before and after liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Effect of ischemia-reperfusion on the incidence of acute cellular rejection and timing of histologic hepatitis C virus recurrence after liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Comparison of hepatitis C histological recurrence rates and patient survival between split and deceased donor liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Treating hepatitis C infection in liver transplant recipients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Is retransplantation an option for recurrent hepatitis C cirrhosis after liver transplantation?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Specific inhibition of hepatitis C virus replication by cyclosporin A.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Natural history of hepatitis C and outcomes following liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Treatment of patients with hepatitis C and cirrhosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Use of livers with microvesicular fat safely expands the donor pool

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Predictors of patient and graft survival following liver transplantation for hepatitis C.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Long-term outcome of hepatitis C infection after liver transplantation

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Virology and pathogenesis of hepatitis C virus recurrence.

30 May 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Contribution of marginal donors to liver transplantation for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Allograft TNFbeta and IL16 polymorphisms influence HCV recurrence and severity after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Natural killer cells in hepatitis C virus recurrence following liver transplantation: what role do they play?

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Preventing hepatitis C virus recurrence in liver transplant recipients: a role for adoptive immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Influence of steroids on HCV recurrence after liver transplantation: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3664282

Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation

29 November 2018

1 reference

12 December 2020

Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C

1 reference

12 December 2020

The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation

1 reference

12 December 2020

Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways

1 reference

12 December 2020

Role of cytokine gene polymorphism in hepatitis C recurrence and allograft rejection among liver transplant recipients

1 reference

12 December 2020

Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome

1 reference

12 December 2020

Hepatic steatosis: a specific sign of hepatitis C reinfection after liver transplantation

1 reference

12 December 2020

HLA-DRB1 Donor-Recipient Mismatch Affects the Outcome of Hepatitis C Disease Recurrence After Liver Transplantation

1 reference

12 December 2020

Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?

1 reference

12 December 2020

Assignment of steatotic livers by the Mayo model for end-stage liver disease

1 reference

12 December 2020

Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts

1 reference

12 December 2020

Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection

1 reference

12 December 2020

Liver Transplantation and Hepatitis C. Proceedings of a consensus development symposium

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V5.I5.237

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.4254/WJH.V5.I5.237

0 references

PMC publication ID

3664282

0 references